|
rs41303343
|
CYP3A5;ZSCAN25
|
ASSAY FOR TACROLIMUS
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.
|
30801552 |
2019 |
|
rs776746
|
CYP3A5;ZSCAN25
|
ASSAY FOR TACROLIMUS
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.
|
30801552 |
2019 |
|
rs12333599
|
CYP3A5;ZSCAN25
|
Platelet Count measurement
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Hormone measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms.
|
21533175 |
2011 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Hypertensive disease
|
|
0.040 |
GeneticVariation |
BEFREE |
Our finding suggested that wild-type CYP3A4 rs2242480 (TT) carriers should be more cautious to take tacrolimus when they are coadministrated with calcium channel blockers, and CYP3A5 rs776746 (AA) carriers may need higher tacrolimus dosage when they are in combination with hypertension.
|
30861159 |
2019 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Hypertensive disease
|
|
0.040 |
GeneticVariation |
BEFREE |
We explored the association between the CYP3A5 (rs776746) gene and hypertension in the Chinese Han population.
|
28448186 |
2017 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Hypertensive disease
|
|
0.040 |
GeneticVariation |
BEFREE |
Overall, no associations were observed between the rs776746 polymorphism and BP/hypertension.
|
21814220 |
2011 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Hypertensive disease
|
|
0.040 |
GeneticVariation |
BEFREE |
The CYP3A5 genotype was related with blood pressure in the general population, but the effect on the risk for hypertension in pregnancy has not been evaluated.We compared the allele and genotype frequencies of three functional SNPs in the CYP3A5 (rs776746), CYP3A4 (rs2740574), and CYP21A2 (rs6471) genes between pregnant women who developed hypertension (n = 250) or who remained normotensive (control group, n = 250).
|
20617557 |
2010 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Tuberculosis
|
|
0.020 |
GeneticVariation |
BEFREE |
The aim of this study was to examine the effect of two gene polymorphisms, one in the CYP2B6 (rs3745274) gene and one in the CYP3A5 (rs776746) gene, on the development of hepatotoxicity in patients treated with anti-TB drugs in a Brazilian Amazon population.
|
25271170 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Cerebrovascular accident
|
|
0.020 |
GeneticVariation |
BEFREE |
The interaction between rs10507391 and rs776746 increases the susceptibility to ischemic stroke and is associated with atherothrombotic events in stroke patients.
|
25534367 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Cerebrovascular accident
|
|
0.020 |
GeneticVariation |
BEFREE |
Eight variants in five candidate genes were examined for the risk of stroke, including the SG13S32 (rs9551963), SG13S42 (rs4769060), SG13S89 (rs4769874), and SG13S114 (rs10507391) variants of the 5-lipoxygenase activating protein (ALOX5AP) gene, the G860A (rs751141) variant of the soluble epoxide hydrolase (EPHX2) gene, the A1075C (rs1057910) variant of the CYP2C9*2 gene, the C430T (rs1799853) variant of the CYP2C9*3 gene, and the A6986G (rs776746) variant of the CYP3A5 gene.
|
24368493 |
2014 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Tuberculosis
|
|
0.020 |
GeneticVariation |
BEFREE |
CYP2C19 (636 G>A, rs4986893) A allele and AG genotype were associated with decreased susceptibility to TB (P = 0.006, OR= 0.33, 95% CI: 0.15-0.76; and P = 0.005, OR =0.31, 95% CI: 0.14-0.72 respectively), as were the CYP3A5 (6986A>G, rs776746) G allele and particularly homozygous GG (recessive mode) genotype (P = 0.004, OR=0.61, 95% CI: 0.43-0.85; and P=0.002, OR=0.47, 95% CI: 0.29-0.76).
|
22771593 |
2012 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Adult Acute Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Variation of the CYP3A5*3 (rs776746 A > G) can lead to oxidation and inactivation of testosterone, which may result in individual susceptibility to prostate cancer.
|
29970707 |
2018 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation |
BEFREE |
Variation of the CYP3A5*3 (rs776746 A > G) can lead to oxidation and inactivation of testosterone, which may result in individual susceptibility to prostate cancer.
|
29970707 |
2018 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Myeloid Leukemia, Chronic
|
|
0.010 |
GeneticVariation |
BEFREE |
Contrasting results have been reported on the role of rs628031 and rs683369 polymorphisms of SLC22A1 and rs776746 of CYP3A5 on imatinib treatment response in patients with chronic myeloid leukemia (CML).
|
29427770 |
2018 |
|
rs15524
|
CYP3A5;ZSCAN25
|
Epilepsy
|
|
0.010 |
GeneticVariation |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Ischemic stroke
|
|
0.010 |
GeneticVariation |
BEFREE |
The interaction between rs10507391 and rs776746 increases the susceptibility to ischemic stroke and is associated with atherothrombotic events in stroke patients.
|
25534367 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs776746 A>G polymorphisms have a prognostic contribution toward FOLFIRI regimen in mCRC.
|
25934339 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Epilepsy
|
|
0.010 |
GeneticVariation |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
|
rs80026734
|
CYP3A5;ZSCAN25
|
Pain
|
|
0.010 |
GeneticVariation |
BEFREE |
The results indicate that among the genetic SNPs we studied which include those affecting analgesic drug metabolism, transport of analgesic agents across the blood-brain barrier, and their activity at target receptors and ion channels and in the modulation of neurotransmitter pathways, the A118G allele variant of OPRM1 has the most potent influence on pain management of postoperative patients.
|
25794200 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Connective Tissue Diseases
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of 72 patients with CTD were recruited in the current study and genotyped for rs776746 in CYP3A5, which showed strong association with TAC concentration in patients with solid organ transplantation.
|
24352002 |
2014 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Chronic Obstructive Airway Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we compared genetic variants influencing the effect of smoking on COPD, that is, the effect of the well-known splicing defect polymorphism, CYP3A5*3 (rs776746), identified before genome-wide association studies, with the genome-wide association studies identified CHRNA3 (rs1051730) polymorphism on the risk of decreased lung function and COPD.
|
24535486 |
2014 |